Accessed December 9, 2023
Food and Drug Administration (FDA) and European Medicines Agency (EMA) approval in 2019 and 2020, respectively, for the second-line treatment of adults with insufficiently controlled T2D to improve glycaemic control as an adjunct to diet and exercise at the once-daily oral doses of 3, 7 and 14 mg [22, 23]
Radoshitzky SR, Longobardi LE, Kuhn JH, Retterer C, Dong L, Clester JC, et al
These injections can target the fat under the chin to help create a more defined jawline
Fermentation of fiber by gut bacteria also produces short-chain fatty acids that directly stimulate L-cells